Skip navigation
Skip navigation

Histone Variant H2A.Z Can Serve as a New Target for Breast Cancer Therapy

Rangasamy, Danny

Description

Histone H2A variant, H2A.Z, plays an essential role in transcriptional activation of ERa-dependent genes, cell proliferation, development, and differentiation. High expression of H2A.Z is ubiquitously detected in the progression of breast cancer, and is significantly associated with lymph node metastasis and patient survival. This makes H2A.Z an excellent target for diagnostic and therapeutic interventions. A recent study provides a new insight into the role of H2A.Z within the context of...[Show more]

dc.contributor.authorRangasamy, Danny
dc.date.accessioned2015-12-10T22:12:06Z
dc.identifier.issn0929-8673
dc.identifier.urihttp://hdl.handle.net/1885/49488
dc.description.abstractHistone H2A variant, H2A.Z, plays an essential role in transcriptional activation of ERa-dependent genes, cell proliferation, development, and differentiation. High expression of H2A.Z is ubiquitously detected in the progression of breast cancer, and is significantly associated with lymph node metastasis and patient survival. This makes H2A.Z an excellent target for diagnostic and therapeutic interventions. A recent study provides a new insight into the role of H2A.Z within the context of cancer-related genes and further corroborates the emerging link between dysfunction of this histone variant and cancer. Interestingly, the depletion of H2A.Z also causes defective in the stability and integrity of the human genome. These abnormalities include defective chromosome segregation, activation of LINE-1 retrotransposable elements, and changes in cell cycle-related genes. This article also presents the molecular pathways linking H2A.Z to breast cancer and mechanisms have been proposed to explain how altered H2A.Z leads to tumorigenesis. Two strategies are proposed here for anti-tumor treatments of H2A.Z-defective breast cancer. One is to restore H2A.Z function by targeting c-Myc transcription factor and the other is to find potential drug treatment by blocking the activity of H2A.Z-remodelling complex, p400/Tip60.
dc.publisherBentham Science Publishers Ltd
dc.sourceCurrent Medicinal Chemistry
dc.subjectKeywords: 10058 f4; anacardic acid; antineoplastic agent; histone H2AZ; Myc protein; unclassified drug; histone; histone H2A.F Z; histone H2A.F-Z; article; breast cancer; cancer growth; cancer therapy; carcinogenesis; cell differentiation; cell proliferation; chrom Breast cancer; C-myc inhibitor; Centromere; Chromatin remodelling complex; Genomic instability; Heterochromatin; Histone variant; Retrotransposons
dc.titleHistone Variant H2A.Z Can Serve as a New Target for Breast Cancer Therapy
dc.typeJournal article
local.description.notesImported from ARIES
local.identifier.citationvolume17
dc.date.issued2010
local.identifier.absfor060199 - Biochemistry and Cell Biology not elsewhere classified
local.identifier.ariespublicationu4020362xPUB187
local.type.statusPublished Version
local.contributor.affiliationRangasamy, Danny, College of Medicine, Biology and Environment, ANU
local.description.embargo2037-12-31
local.bibliographicCitation.issue28
local.bibliographicCitation.startpage3155
local.bibliographicCitation.lastpage3161
local.identifier.doi10.2174/092986710792231941
dc.date.updated2016-02-24T10:27:08Z
local.identifier.scopusID2-s2.0-79952197153
CollectionsANU Research Publications

Download

File Description SizeFormat Image
01_Rangasamy_Histone_Variant_H2A.Z_Can_2010.pdf165.12 kBAdobe PDF    Request a copy


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator